Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Adult Volunteers

Interventions: Drug: Lazertinib(G001)
Drug: Lazertinib(G002)

First Posted Date: 2021-12-17

Last Posted Date: 2024-12-11

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 38

Registration Number: NCT05162274

Locations: 🇰🇷
Seoul National University Hospital Clinical Trial Center, Seoul, Korea, Republic of

A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases

Phase 1

Completed

Conditions: Atopic Healthy Subjects
Adult Subjects with Mild Allergic Diseases

Interventions: Drug: YH35324
Drug: Placebo
Drug: Omalizumab

First Posted Date: 2021-09-29

Last Posted Date: 2024-12-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 68

Registration Number: NCT05061524

Locations: 🇰🇷
Ajou University Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University Health System, Sinchon-dong, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Gumi, Sungnamsi, Korea, Republic of

and more 1 locations

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer
Renal Impairments

Interventions: Drug: YHD1119 75mg

First Posted Date: 2021-08-19

Last Posted Date: 2022-06-30

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 16

Registration Number: NCT05012436

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

Phase 4

Conditions: Diabetic Peripheral Neuropathy

Interventions: Drug: Pregabalin 150mg + Alpha-lipoic acid 480mg
Drug: Pregabalin 150mg
Drug: Alpha-Lipoic Acid 480mg

First Posted Date: 2021-04-15

Last Posted Date: 2021-06-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 150

Registration Number: NCT04846673

Locations: 🇰🇷
Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of

Early Access Program of Lazertinib in Republic of Korea

Conditions: Lung Cancer

First Posted Date: 2021-04-02

Last Posted Date: 2022-03-03

Lead Sponsor: Yuhan Corporation

Registration Number: NCT04829422

Bioequivalence Study Between YHP1906 Tab. 5 mg and YHR1902 Tab. 5 mg

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: YHP1906
Drug: YHR1902

First Posted Date: 2020-03-20

Last Posted Date: 2020-05-26

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 30

Registration Number: NCT04316065

Locations: 🇰🇷
Metro Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gefitinib 250 mg
Drug: Lazertinib 240 mg/160 mg
Drug: Lazertinib-matching placebo 240 mg/160 mg
Drug: Gefitinib-matching placebo 250 mg

First Posted Date: 2020-01-30

Last Posted Date: 2024-12-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 393

Registration Number: NCT04248829

Locations: 🇵🇭
Perpetual Succour Hospital, Cebu, Philippines
🇹🇭
Prince of Songkla University, Hat Yai, Thailand
🇺🇦
Tsentralna miska klinichna likarnia, Úzhgorod, Zakarpats'ka Oblast', Ukraine

and more 77 locations

Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: YHP1903
Drug: Champix

First Posted Date: 2020-01-13

Last Posted Date: 2020-01-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 34

Registration Number: NCT04225052

Locations: 🇰🇷
Chonbuk national university hospital, Jeonju, Jeollabuk-do, Korea, Republic of

Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome

Phase 4

Completed

Conditions: Acute Coronary Syndrome
Carotid Atherosclerotic Plaque With Inflammation

Interventions: Drug: high-dose rosuvastatin
Drug: low-dose rosuvastatin plus ezetimibe

First Posted Date: 2019-08-14

Last Posted Date: 2019-08-16

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 50

Registration Number: NCT04056169

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia

Phase 4

Completed

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: Amlodipine/Atorvastatin 5/20mg
Drug: Rosuampin 20/5mg
Drug: Rosuampin 10/5mg

First Posted Date: 2019-05-15

Last Posted Date: 2022-10-12

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 259

Registration Number: NCT03951207

Locations: 🇰🇷
Daegu Catholic Univ. Medical Center, Daegu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy